The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET).
 
Susumu Hijioka
Honoraria - Novartis; Teijin Pharma
 
Yoshitaka Honma
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly; Merck Serono; MSD; Novartis; Nutrisystem; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Consulting or Advisory Role - Eisai; Janssen; Rakuten Medical Japan
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly; Merck Serono; MSD; Novartis; Nutrisystem; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Adlai Nortye; Astellas Pharma; AstraZeneca; Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma; Genmab; GlaxoSmithKline; Janssen; Maruho; Merck Serono; MSD; Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical Japan (Inst); Taiho Pharmaceutical
 
Nozomu Machida
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - ALX Oncology (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Nobumasa Mizuno
Honoraria - Miyarisan pharmaceutical; Novartis; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; MSD
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Incyte (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Seagen (Inst); SERVIER (Inst)
 
Tetsuya Hamaguchi
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol Myers Squibb Foundation (Inst); Chugai Pharma (Inst); Incyte Japan (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Daiichi-Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
 
Ryo Sadachi
No Relationships to Disclose
 
Nobuyoshi Hiraoka
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Kyowa Kirin International; Myriad Genetics; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience; Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst); Sysmex (Inst)
 
Hidekazu Hirano
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Taiho Pharmaceutical (Inst)
 
Shogen Boku
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Daiichi Sankyo Co. Ltd. (Inst)
 
Masafumi Ikeda
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Satoshi Takeuchi
No Relationships to Disclose
 
Noriyoshi Fukushima
Consulting or Advisory Role - Kowa
 
Motohiro Kojima
No Relationships to Disclose
 
Noriko Mitome
No Relationships to Disclose
 
Yusuke Sano
No Relationships to Disclose
 
Takaki Yoshikawa
Honoraria - Astellas Pharma; AstraZeneca; BMS; Chugai Pharma; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson/Janssen; Medtronic; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - MSD Oncology; TERUMO
Research Funding - Lilly
 
Yukihide Kanemitsu
Honoraria - Covidien; Ethicon
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chiome Bioscience (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Japan Clinical Oncology Group
No Relationships to Disclose